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LETTERS TO THE EDITOR
Procainamide Pharmacokinetics and Diuretic
and Fluid Administration
The article by Kessler et al. (I) on procainamide pharmacokinetics
is of interest. Although the volume of distribution is not a real
volume, its calculation can be significantly affected by changes in
extracellular volume, which may in turn be brought about by
changes in diuretic dose or the quantity of fluids administered. As
the authors state, volume of distribution is inversely related to
serum drug concentration, a measurement that could be readily
changed by changes in extracellular volume. Is it known that
diuretic dose and fluid administration were held constant for all
patients throughout the study? This would have to be the case
before we could have confidence in the group means.
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81 Columbia Turnpike
Rensselaer, New York 12144
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Reply
Each patient was studied during a stable period wherein diuretic
and fluid administration were kept constant for each individual.
Moreover, with a calculated volume of distribution of procain-
amide averaging almost 2 liters/kg we would expect tissue per-
fusion/concentration factors to be the major determinant of drug
volume of distribution (at steady state), For instance a 5 liter (II
pound) delta in extracellular volume would represent less than a
3% change in the volume of distribution (even if these were directly
related, which they are probably not). We hope this explanation
clarifies the issue.
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Atrial Sensing After Dual Chamber Pulse
Generator Implantation
Klementowicz and Furman (1) observed the evolution of atrial
sensing after dual chamber pulse generator implantation. Of 54
patients, sensing deteriorated in 26% (mean follow-up 58 weeks)
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and fluctuated in 20%, without associated increase in pacing
threshold. The authors did not mention any clinical problem: the
sensitivity setting was readjusted and all pacemakers remained in
the DDD mode. We observed two patients in whom such atrial
sensing deterioration was associated with clinical problems. Both
received a dual chamber generator (Telectronics, Autima II), with
a unipolar atrial J electrode (Telectronics, 030-403). Atrial sen-
sitivity (two settings: 0.5 and 1 mY) was initially set at I mY.
Radiologic follow-up did not show any atrial lead dislodgment.
Increase in pacing threshold was not noticed. Drugs were not
changed, and new cardiac problems (such as ischemia) did not
occur. The first patient (an 81 year old woman with symptomatic
sick sinus syndrome, without known tachyarrhythmias; atrial sig-
nal during implantation: 2 mV) had two symptomatic episodes of
atrial fibrillation 3 weeks after implantation. The second episode
occurred during Holter monitoring. It showed the clear atrial un-
dersensing (in the hours before atrial fibrillation) probably re-
sponsible for it, by pacing during the atrial vulnerable period (2).
Further evolution was uneventful (follow-up 8 months), the atrial
sensitivity setting was not changed and atrial undersensing and
atrial fibrillation did not recur.
The second patient (a 79 year old man with symptomatic mixed
carotid sinus hypersensitivity; atrial signal during implantation:
3.7 mV) remained free of syncope and of any problem with his
pacemaker during 14 months. He was then readmitted for syncope
with epilepsy, attributed to an ischemic stroke. Atrial undersensing
was present and intermittent (sometimes from beat to beat). Atrial
fibrillation was never found. Resetting atrial sensitivity to 0.5 mV
did not change the undersensing. No influence of breathing or
position, and no abnormal motion of atrial lead were found. DDD
mode was abandoned (although we did not think that the under-
sensing was responsible for the syncope).
In conclusion, we agree that atrial sensing must be continually
monitored (I), because atrial undersensing may generate clinical
problems, such as atrial fibrillation or a need to change the pacing
mode.
ALAIN FRIART, MD
MICHEL PAESMANS, MD
YVON DEVALERIOLA, MD
Department of Cardiology
Centre Hospitalier de Tivoli
B 7100 La Louviere, Belgium
References
I. Klementowicz P, Furman S. Stability of atrial sensing and pacing after dual
chamber pulse generator implantation. J Am Coli Cardiol 1985;6:1338-41.
2. Furman S, Cooper J. Atrial fibrillation during A-V sequential pacing. Pace
1982:5:133-5.
